715 related articles for article (PubMed ID: 21803743)
1. DLL4-Notch signaling mediates tumor resistance to anti-VEGF therapy in vivo.
Li JL; Sainson RC; Oon CE; Turley H; Leek R; Sheldon H; Bridges E; Shi W; Snell C; Bowden ET; Wu H; Chowdhury PS; Russell AJ; Montgomery CP; Poulsom R; Harris AL
Cancer Res; 2011 Sep; 71(18):6073-83. PubMed ID: 21803743
[TBL] [Abstract][Full Text] [Related]
2. Delta-like 4 Notch ligand regulates tumor angiogenesis, improves tumor vascular function, and promotes tumor growth in vivo.
Li JL; Sainson RC; Shi W; Leek R; Harrington LS; Preusser M; Biswas S; Turley H; Heikamp E; Hainfellner JA; Harris AL
Cancer Res; 2007 Dec; 67(23):11244-53. PubMed ID: 18056450
[TBL] [Abstract][Full Text] [Related]
3. Dll4 Blockade in Stromal Cells Mediates Antitumor Effects in Preclinical Models of Ovarian Cancer.
Kuhnert F; Chen G; Coetzee S; Thambi N; Hickey C; Shan J; Kovalenko P; Noguera-Troise I; Smith E; Fairhurst J; Andreev J; Kirshner JR; Papadopoulos N; Thurston G
Cancer Res; 2015 Oct; 75(19):4086-96. PubMed ID: 26377940
[TBL] [Abstract][Full Text] [Related]
4. New pathways and mechanisms regulating and responding to Delta-like ligand 4-Notch signalling in tumour angiogenesis.
Oon CE; Harris AL
Biochem Soc Trans; 2011 Dec; 39(6):1612-8. PubMed ID: 22103496
[TBL] [Abstract][Full Text] [Related]
5. The vascular delta-like ligand-4 (DLL4)-Notch4 signaling correlates with angiogenesis in primary glioblastoma: an immunohistochemical study.
Zhang JF; Chen Y; Qiu XX; Tang WL; Zhang JD; Huang JH; Lin GS; Wang XF; Lin ZX
Tumour Biol; 2016 Mar; 37(3):3797-805. PubMed ID: 26472724
[TBL] [Abstract][Full Text] [Related]
6. Mediators of glioblastoma resistance and invasion during antivascular endothelial growth factor therapy.
Lucio-Eterovic AK; Piao Y; de Groot JF
Clin Cancer Res; 2009 Jul; 15(14):4589-99. PubMed ID: 19567589
[TBL] [Abstract][Full Text] [Related]
7. Delta-like 4/Notch signaling and its therapeutic implications.
Yan M; Plowman GD
Clin Cancer Res; 2007 Dec; 13(24):7243-6. PubMed ID: 18094402
[TBL] [Abstract][Full Text] [Related]
8. Delta-like ligand 4-targeted nanomedicine for antiangiogenic cancer therapy.
Liu YR; Guan YY; Luan X; Lu Q; Wang C; Liu HJ; Gao YG; Yang SC; Dong X; Chen HZ; Fang C
Biomaterials; 2015 Feb; 42():161-71. PubMed ID: 25542804
[TBL] [Abstract][Full Text] [Related]
9. The Notch ligand Delta-like 4 negatively regulates endothelial tip cell formation and vessel branching.
Suchting S; Freitas C; le Noble F; Benedito R; Bréant C; Duarte A; Eichmann A
Proc Natl Acad Sci U S A; 2007 Feb; 104(9):3225-30. PubMed ID: 17296941
[TBL] [Abstract][Full Text] [Related]
10. Regulation of CXCR4 by the Notch ligand delta-like 4 in endothelial cells.
Williams CK; Segarra M; Sierra Mde L; Sainson RC; Tosato G; Harris AL
Cancer Res; 2008 Mar; 68(6):1889-95. PubMed ID: 18339870
[TBL] [Abstract][Full Text] [Related]
11. Synaptojanin-2 binding protein stabilizes the Notch ligands DLL1 and DLL4 and inhibits sprouting angiogenesis.
Adam MG; Berger C; Feldner A; Yang WJ; Wüstehube-Lausch J; Herberich SE; Pinder M; Gesierich S; Hammes HP; Augustin HG; Fischer A
Circ Res; 2013 Nov; 113(11):1206-18. PubMed ID: 24025447
[TBL] [Abstract][Full Text] [Related]
12. Cross-talk between leukemic and endothelial cells promotes angiogenesis by VEGF activation of the Notch/Dll4 pathway.
Zhang J; Ye J; Ma D; Liu N; Wu H; Yu S; Sun X; Tse W; Ji C
Carcinogenesis; 2013 Mar; 34(3):667-77. PubMed ID: 23239744
[TBL] [Abstract][Full Text] [Related]
13. Dll4 blockade potentiates the anti-tumor effects of VEGF inhibition in renal cell carcinoma patient-derived xenografts.
Miles KM; Seshadri M; Ciamporcero E; Adelaiye R; Gillard B; Sotomayor P; Attwood K; Shen L; Conroy D; Kuhnert F; Lalani AS; Thurston G; Pili R
PLoS One; 2014; 9(11):e112371. PubMed ID: 25393540
[TBL] [Abstract][Full Text] [Related]
14. Anti-VEGF antibody therapy induces tumor hypoxia and stanniocalcin 2 expression and potentiates growth of human colon cancer xenografts.
Miyazaki S; Kikuchi H; Iino I; Uehara T; Setoguchi T; Fujita T; Hiramatsu Y; Ohta M; Kamiya K; Kitagawa K; Kitagawa M; Baba S; Konno H
Int J Cancer; 2014 Jul; 135(2):295-307. PubMed ID: 24375080
[TBL] [Abstract][Full Text] [Related]
15. Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis.
Noguera-Troise I; Daly C; Papadopoulos NJ; Coetzee S; Boland P; Gale NW; Lin HC; Yancopoulos GD; Thurston G
Nature; 2006 Dec; 444(7122):1032-7. PubMed ID: 17183313
[TBL] [Abstract][Full Text] [Related]
16. Delta-like 4/Notch signaling promotes Apc
Badenes M; Trindade A; Pissarra H; Lopes-da-Costa L; Duarte A
BMC Cancer; 2017 Jan; 17(1):50. PubMed ID: 28086833
[TBL] [Abstract][Full Text] [Related]
17. Role of Delta-like 4 in Jagged1-induced tumour angiogenesis and tumour growth.
Oon CE; Bridges E; Sheldon H; Sainson RCA; Jubb A; Turley H; Leek R; Buffa F; Harris AL; Li JL
Oncotarget; 2017 Jun; 8(25):40115-40131. PubMed ID: 28445154
[TBL] [Abstract][Full Text] [Related]
18. Antiangiogenic mechanisms of PJ-8, a novel inhibitor of vascular endothelial growth factor receptor signaling.
Huang SW; Lien JC; Kuo SC; Huang TF
Carcinogenesis; 2012 May; 33(5):1022-30. PubMed ID: 22436611
[TBL] [Abstract][Full Text] [Related]
19. Endothelial-specific Notch blockade inhibits vascular function and tumor growth through an eNOS-dependent mechanism.
Patenaude A; Fuller M; Chang L; Wong F; Paliouras G; Shaw R; Kyle AH; Umlandt P; Baker JH; Diaz E; Tong J; Minchinton AI; Karsan A
Cancer Res; 2014 May; 74(9):2402-11. PubMed ID: 24599126
[TBL] [Abstract][Full Text] [Related]
20. Delta-like ligand 4-notch blockade and tumor radiation response.
Liu SK; Bham SA; Fokas E; Beech J; Im J; Cho S; Harris AL; Muschel RJ
J Natl Cancer Inst; 2011 Dec; 103(23):1778-98. PubMed ID: 22010178
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
